2-(sec-butyldisulfanyl)thiazole | 514207-38-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(sec-butyldisulfanyl)thiazole
• 英文别名: 2-(butan-2-yldisulfanyl)-1,3-thiazole
• CAS: 514207-38-6
• 化学式: C₇H₁₁NS₃
• 分子量: 205.369
• InChiKey: NLEPKZJPFCAMTO-UHFFFAOYSA-N

物化性质

• 沸点：
  295.9±23.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  91.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-丁硫醇 、 2-巯基噻唑 在 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 以84%的产率得到2-(sec-butyldisulfanyl)thiazole
  参考文献：
  名称：

  Selective Inhibition of Extracellular Thioredoxin by Asymmetric Disulfides

  摘要：

  Whereas the role of mammalian thioredoxin (Trx) as an intracellular protein cofactor is widely appreciated, its function in the extracellular environment is not well-understood. Only few extracellular targets of Trx-mediated thiol disulfide exchange are known. For example, Trx activates extracellular transglutaminase 2 (TG2) via reduction of an intramolecular disulfide bond. Because hyperactive TG2 is thought to play a role in various diseases, understanding the biological role of utracellular Trx may provide critical insight into the pathogenesis of these disorders. Starting from a clinical-stage asymmetric disulfide lead, we have identified analogs with >100-fold specificity for Trx. Structure-activity relationship and computational docking model analyses have provided insights into the features important for enhancing potency and specificity. The most active compound identified had an IC50 below 0.1 mu M in cell culture and may be appropriate for in vivo use to interrogate the role of extracellular Trx in health and disease.

  DOI：

  10.1021/jm301775s

文献信息

• Methods and compositions to prevent or treat bacterial infections
  申请人：Ketter Patrick

  公开号：US10398682B2

  公开（公告）日：2019-09-03

  Certain embodiments are directed to methods and compositions for preventing or treating bacterial infections. In certain embodiments the compositions comprise thioredoxin inhibitors, and/or thioredoxin-like inhibitors.

  某些实施方案涉及预防或治疗细菌感染的方法和组合物。在某些实施方案中，组合物包括硫氧还蛋白抑制剂和/或硫氧还蛋白样抑制剂。
• Modulation of Tissue Transglutaminase Activation in Disease
  申请人：DiRaimondo Thomas

  公开号：US20140322278A1

  公开（公告）日：2014-10-30

  Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activation of TG2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, Crohn's Disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric tissues, in particular the paracellular transport of molecules greater than about 500 mw, e.g. peptides, including without limitation immunogenic gluten peptides.
• METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS
  申请人：KETTER Patrick

  公开号：US20160151333A1

  公开（公告）日：2016-06-02

  Certain embodiments are directed to methods and compositions for preventing or treating bacterial infections. In certain embodiments the compositions comprise thioredoxin inhibitors, and/or thioredoxin-like inhibitors.
• MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20170266198A1

  公开（公告）日：2017-09-21

  Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activation of TG2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, Crohn's Disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric tissues, in particular the paracellular transport of molecules greater than about 500 mw, e.g. peptides, including without limitation immunogenic gluten peptides.
• [EN] MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE<br/>[FR] MODULATION DE L'ACTIVATION DE LA TRANSGLUTAMINASE TISSULAIRE DANS UNE MALADIE
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2012177640A2

  公开（公告）日：2012-12-27

  Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activation of TG2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, Crohn's Disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric tissues, in particular the paracellular transport of molecules greater than about 500 mw, e.g. peptides, including without limitation immunogenic gluten peptides.